Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040 : a modelling study
Copyright © 2022 Elsevier Ltd. All rights reserved..
BACKGROUND: Accurate data on type 1 diabetes prevalence, incidence, associated mortality and life expectancy are crucial to inform public health policy, but these data are scarce. We therefore developed a model based on available data to estimate these values for 201 countries for the year 2021 and estimate the projected prevalent cases in 2040.
METHODS: We fitted a discrete-time illness-death model (Markov model) to data on type 1 diabetes incidence and type 1 diabetes-associated mortality to produce type 1 diabetes prevalence, incidence, associated mortality and life expectancy in all countries. Type 1 diabetes incidence and mortality data were available from 97 and 37 countries respectively. Diagnosis rates were estimated using data from an expert survey. Mortality was modelled using random-forest regression of published type 1 diabetes mortality data, and life expectancy was calculated accordingly using life tables. Estimates were validated against observed prevalence data for 15 countries. We also estimated missing prevalence (the number of additional people who would be alive with type 1 diabetes if their mortality matched general population rates).
FINDINGS: In 2021, there were about 8·4 (95% uncertainty interval 8·1-8·8) million individuals worldwide with type 1 diabetes: of these 1·5 million (18%) were younger than 20 years, 5·4 million (64%) were aged 20-59 years, and 1·6 million (19%) were aged 60 years or older. In that year there were 0·5 million new cases diagnosed (median age of onset 39 years), about 35 000 non-diagnosed individuals died within 12 months of symptomatic onset. One fifth (1·8 million) of individuals with type 1 diabetes were in low-income and lower-middle-income countries. Remaining life expectancy of a 10-year-old diagnosed with type 1 diabetes in 2021 ranged from a mean of 13 years in low-income countries to 65 years in high-income countries. Missing prevalent cases in 2021 were estimated at 3·7 million. In 2040, we predict an increase in prevalent cases to 13·5-17·4 million (60-107% higher than in 2021) with the largest relative increase versus 2021 in low-income and lower-middle-income countries.
INTERPRETATION: The burden of type 1 diabetes in 2021 is vast and is expected to increase rapidly, especially in resource-limited countries. Most incident and prevalent cases are adults. The substantial missing prevalence highlights the premature mortality of type 1 diabetes and an opportunity to save and extend lives of people with type 1 diabetes. Our new model, which will be made publicly available as the Type 1 Diabetes Index model, will be an important tool to support health delivery, advocacy, and funding decisions for type 1 diabetes.
FUNDING: JDRF International.
| Errataetall: |
CommentIn: Lancet Diabetes Endocrinol. 2022 Oct;10(10):688-689. - PMID 36113506 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
The lancet. Diabetes & endocrinology - 10(2022), 10 vom: 01. Okt., Seite 741-760 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gregory, Gabriel A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 28.09.2022 Date Revised 03.11.2022 published: Print-Electronic CommentIn: Lancet Diabetes Endocrinol. 2022 Oct;10(10):688-689. - PMID 36113506 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S2213-8587(22)00218-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346302439 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346302439 | ||
| 003 | DE-627 | ||
| 005 | 20231226031114.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S2213-8587(22)00218-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1154.xml |
| 035 | |a (DE-627)NLM346302439 | ||
| 035 | |a (NLM)36113507 | ||
| 035 | |a (PII)S2213-8587(22)00218-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gregory, Gabriel A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040 |b a modelling study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.09.2022 | ||
| 500 | |a Date Revised 03.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Lancet Diabetes Endocrinol. 2022 Oct;10(10):688-689. - PMID 36113506 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Accurate data on type 1 diabetes prevalence, incidence, associated mortality and life expectancy are crucial to inform public health policy, but these data are scarce. We therefore developed a model based on available data to estimate these values for 201 countries for the year 2021 and estimate the projected prevalent cases in 2040 | ||
| 520 | |a METHODS: We fitted a discrete-time illness-death model (Markov model) to data on type 1 diabetes incidence and type 1 diabetes-associated mortality to produce type 1 diabetes prevalence, incidence, associated mortality and life expectancy in all countries. Type 1 diabetes incidence and mortality data were available from 97 and 37 countries respectively. Diagnosis rates were estimated using data from an expert survey. Mortality was modelled using random-forest regression of published type 1 diabetes mortality data, and life expectancy was calculated accordingly using life tables. Estimates were validated against observed prevalence data for 15 countries. We also estimated missing prevalence (the number of additional people who would be alive with type 1 diabetes if their mortality matched general population rates) | ||
| 520 | |a FINDINGS: In 2021, there were about 8·4 (95% uncertainty interval 8·1-8·8) million individuals worldwide with type 1 diabetes: of these 1·5 million (18%) were younger than 20 years, 5·4 million (64%) were aged 20-59 years, and 1·6 million (19%) were aged 60 years or older. In that year there were 0·5 million new cases diagnosed (median age of onset 39 years), about 35 000 non-diagnosed individuals died within 12 months of symptomatic onset. One fifth (1·8 million) of individuals with type 1 diabetes were in low-income and lower-middle-income countries. Remaining life expectancy of a 10-year-old diagnosed with type 1 diabetes in 2021 ranged from a mean of 13 years in low-income countries to 65 years in high-income countries. Missing prevalent cases in 2021 were estimated at 3·7 million. In 2040, we predict an increase in prevalent cases to 13·5-17·4 million (60-107% higher than in 2021) with the largest relative increase versus 2021 in low-income and lower-middle-income countries | ||
| 520 | |a INTERPRETATION: The burden of type 1 diabetes in 2021 is vast and is expected to increase rapidly, especially in resource-limited countries. Most incident and prevalent cases are adults. The substantial missing prevalence highlights the premature mortality of type 1 diabetes and an opportunity to save and extend lives of people with type 1 diabetes. Our new model, which will be made publicly available as the Type 1 Diabetes Index model, will be an important tool to support health delivery, advocacy, and funding decisions for type 1 diabetes | ||
| 520 | |a FUNDING: JDRF International | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Robinson, Thomas I G |e verfasserin |4 aut | |
| 700 | 1 | |a Linklater, Sarah E |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Colagiuri, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a de Beaufort, Carine |e verfasserin |4 aut | |
| 700 | 1 | |a Donaghue, Kim C |e verfasserin |4 aut | |
| 700 | 0 | |a International Diabetes Federation Diabetes Atlas Type 1 Diabetes in Adults Special Interest Group |e verfasserin |4 aut | |
| 700 | 1 | |a Magliano, Dianna J |e verfasserin |4 aut | |
| 700 | 1 | |a Maniam, Jayanthi |e verfasserin |4 aut | |
| 700 | 1 | |a Orchard, Trevor J |e verfasserin |4 aut | |
| 700 | 1 | |a Rai, Priyanka |e verfasserin |4 aut | |
| 700 | 1 | |a Ogle, Graham D |e verfasserin |4 aut | |
| 700 | 1 | |a Harding, Jessica L |e investigator |4 oth | |
| 700 | 1 | |a Wander, Pandora L |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Xinge |e investigator |4 oth | |
| 700 | 1 | |a Li, Xia |e investigator |4 oth | |
| 700 | 1 | |a Karuranga, Suvi |e investigator |4 oth | |
| 700 | 1 | |a Chen, Hongzhi |e investigator |4 oth | |
| 700 | 1 | |a Sun, Hong |e investigator |4 oth | |
| 700 | 1 | |a Xie, Yuting |e investigator |4 oth | |
| 700 | 1 | |a Oram, Richard |e investigator |4 oth | |
| 700 | 1 | |a Magliano, Dianna J |e investigator |4 oth | |
| 700 | 1 | |a Zhou, Zhiguang |e investigator |4 oth | |
| 700 | 1 | |a Jenkins, Alicia J |e investigator |4 oth | |
| 700 | 1 | |a Ma, Ronald Cw |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet. Diabetes & endocrinology |d 2013 |g 10(2022), 10 vom: 01. Okt., Seite 741-760 |w (DE-627)NLM233773398 |x 2213-8595 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:10 |g day:01 |g month:10 |g pages:741-760 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S2213-8587(22)00218-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 10 |b 01 |c 10 |h 741-760 | ||